Marshall Wace, LLP Protagonist Therapeutics, Inc Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 315,373 shares of PTGX stock, worth $12.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

315,373

Previous 572,177 44.88%

Holding current value

$12.8 Million

Previous $19.8 Million 28.51%

% of portfolio

0.02%

Previous 0.03%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $8.66 Million - $12.2 Million	-256,804 Reduced 44.88%	315,373 $14.2 Million
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $9.98 Million - $14.1 Million	-404,716 Reduced 41.43%	572,177 $19.8 Million
Q1 2024 May 15, 2024	BUY	$21.79 - $32.15 $18.2 Million - $26.8 Million	834,423 Added 585.68%	976,893 $28.3 Million
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $1.7 Million - $2.83 Million	120,723 Added 555.12%	142,470 $3.27 Million
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $2.38 Million - $3.38 Million	-142,753 Reduced 86.78%	21,747 $362,000
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $21.7 Million - $35.3 Million	-1,201,580 Reduced 87.96%	164,500 $4.54 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $952,585 - $2.24 Million	-88,366 Reduced 6.08%	1,366,080 $31.4 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $4.71 Million - $7.15 Million	639,720 Added 78.52%	1,454,446 $15.9 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $2.76 Million - $4.11 Million	350,669 Added 75.57%	814,726 $6.87 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $3.28 Million - $11.8 Million	464,057 New	464,057 $3.67 Million
Q2 2021 Aug 13, 2021	SELL	$25.57 - $44.88 $2.22 Million - $3.89 Million	-86,691 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $572,559 - $937,708	-30,103 Reduced 25.77%	86,691 $2.25 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $2.16 Million - $2.94 Million	116,794 New	116,794 $2.35 Million
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $167,488 - $294,751	-17,799 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $159,835 - $230,675	17,799 New	17,799 $216,000

Others Institutions Holding PTGX

# of Institutions

248

Shares Held

56.7M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.99B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Protagonist Therapeutics, Inc Transaction History